Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer

Carissa E. Chu, Mohammed Alshalalfa, Martin Sjöström, Shuang G. Zhao, Yang Liu, Jonathan Chou, Annika Herlemann, Brandon Mahal, Amar Kishan, Daniel E. Spratt, Matthew Cooperberg, Eric Small, Anthony Wong, Sima Porten, Thomas A. Hope, Ashley E. Ross, Elai Davicioni, Paul Nguyen, R. Jeffrey Karnes, Peter R. CarrollEdward Schaeffer, Felix Y. Feng*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

18F-Fluciclovine-based positron emission tomography (PET) imaging is recommended in the USA for biochemical recurrence (BCR) after prostate cancer treatment. However, prostate-specific membrane antigen (PSMA)-based PET imaging is more common worldwide, supported by international guidelines, and is now approved by the Food and Drug Administration in the USA for initial staging of primary prostate cancer. Little is known about the molecular profiles of lesions detected by PSMA-targeted PET/computed tomography (CT) versus 18F-fluciclovine PET/CT. We examined the expression of PSMA (FOLH1) and the fluciclovine transporter genes LAT1–4 and ASCT1/2 in a combined cohort of more than 18 000 radical prostatectomy specimens and their associations with clinical outcomes. Expression of PSMA and all but one fluciclovine transporter gene was higher in prostate cancer than in benign tissue. PSMA expression was associated with Gleason score (GS) ≥8 and lymph node involvement (LNI), and had a positive linear correlation with Decipher risk score. By contrast, expression of the fluciclovine transporters LAT2, LAT3, and ASCT2 was negatively associated with GS ≥ 8, LNI, and high Decipher score. The top decile of PSMA expression was associated with poorest metastasis-free survival (MFS), while the bottom deciles of LAT3 and ASCT2 expression were associated with poorest MFS. Patient summary: We measured the expression of genes that encode the targets for two different radiotracers in PET (positron emission tomography) scans of the prostate. We found that PSMA gene expression (PSMA-based tracer) is associated with worse clinical outcomes, while expression of ASCT2, LAT2, and LAT3 genes (fluciclovine tracer) is associated with better outcomes.

Original languageEnglish (US)
JournalEuropean urology
DOIs
StateAccepted/In press - 2021

Keywords

  • Fluciclovine transporter
  • Gene expression
  • Nuclear imaging
  • Prostate cancer
  • Prostate-specific membrane antigen

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer'. Together they form a unique fingerprint.

Cite this